Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Novo Holdings A/S

Q2 2023 · 13F-HR

Novo Holdings A/Sholdings as filed

Filed 2023-08-14 · accession 0000950123-23-007714

$1.29B
Reported value
41
Positions
2023-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
N07059210ASMLASML HOLDING N V$143.3M11.1%197,760CommonSOLE
79466L302CRMSALESFORCE.COM, INC.$112.1M8.66%530,500CommonSOLE
51655R101LANZATECH GLOBAL INC$108.0M8.35%15,814,845CommonSOLE
218352102CORTCORCEPT THERAPEUTICS INC$75.2M5.81%3,377,768CommonSOLE
874039100TSMTAIWAN SEMICONDUCTOR MFG LTD$71.7M5.54%710,780CommonSOLE
12685J105CABOCABLE ONE INC$61.8M4.78%94,103CommonSOLE
254604101IRONDISC MEDICINE, INC.$48.4M3.74%1,090,772CommonSOLE
28036F105EWTXEDGEWISE THERAPEUTICS INC$47.1M3.64%6,071,703CommonSOLE
604749101MIRMMIRUM PHARMACEUTICALS INC$43.6M3.37%1,684,193CommonSOLE
037833100AAPLAPPLE INC$43.0M3.32%221,460CommonSOLE
92243G108PCVXVAXCYTE INC$42.2M3.26%845,000CommonSOLE
01609W102BABAALIBABA GROUP HLDG LTD$41.7M3.23%500,827CommonSOLE
09061G101BMRNBIOMARIN PHARMACEUTICAL INC$34.7M2.68%400,000CommonSOLE
03940C100ACLXGBXARCELLX, INC.$31.6M2.44%1,000,000CommonSOLE
81181C104SEAGEN INC.$30.8M2.38%159,986CommonSOLE
09627Y1092655787DBLUEPRINT MEDICINES CORP$28.4M2.19%448,804CommonSOLE
457669307INSMINSMED INC$28.3M2.18%1,339,304CommonSOLE
03152W109AM6AMICUS THERAPEUTICS INC$26.3M2.03%2,095,900CommonSOLE
02043Q107ALNYALNYLAM PHARMACEUTICALS INC$22.5M1.74%118,383CommonSOLE
23257D103CBAYUSDCYMABAY THERAPEUTICS INC$21.9M1.69%2,000,000CommonSOLE
75974E103RENEO PHARMACEUTICALS INC$21.8M1.69%3,330,377CommonSOLE
112585104BROOKFIELD ASSET MGMT INC$20.5M1.58%627,207CommonSOLE
N69605108PHVSPHARVARIS N V$20.1M1.56%1,329,325CommonSOLE
22663K107CRNXCRINETICS PHARMACEUTICALS IN$19.8M1.53%1,100,000CommonSOLE
77313F106RCKTROCKET PHARMACEUTICALS INC$18.3M1.41%920,000CommonSOLE
35104E100FDMT4D MOLECULAR THERAPEUTICS IN$18.1M1.40%1,000,000CommonSOLE
85209E109SPRUCE BIOSCIENCES INC$14.5M1.12%6,722,336CommonSOLE
75120L100RALLYBIO CORP$12.4M0.96%2,187,999CommonSOLE
82710M100SILKUSDSILK RD MED INC$10.8M0.84%333,884CommonSOLE
457730109INSPINSPIRE MED SYS INC$10.6M0.82%32,500CommonSOLE
23284P103CYTEIR THERAPEUTICS INC$9.5M0.74%3,662,636CommonSOLE
92539P101VERVE THERAPEUTICS INC$9.4M0.72%500,000CommonSOLE
89455T109TMCITREACE MED CONCEPTS INC$9.2M0.71%360,000CommonSOLE
00288U106ABCLABCELLERA BIOLOGICS INC$7.3M0.56%1,126,915CommonSOLE
36338D108GRTXGALERA THERAPEUTICS INC$6.6M0.51%2,100,000CommonSOLE
449778109IOBTQIO BIOTECH INC$6.4M0.50%3,277,932CommonSOLE
36322Q107GLTOUSDGALECTO INC$6.3M0.49%2,497,791CommonSOLE
N515171054PKBLAVA THERAPEUTICS NV$4.9M0.38%2,400,000CommonSOLE
49705R105KNTEUSDKINNATE BIOPHARMA INC$2.5M0.19%815,707CommonSOLE
57142B104MQMARQETA INC$2.2M0.17%441,558CommonSOLE
84833T103SPROSPERO THERAPEUTICS INC$679,9080.05%468,902CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.